A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy

• Status: Recruiting
• Trial end date: 2024-06-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eisai Inc.

Criteria

Inclusion Criteria:

• Male or female participants. Cohort 1: age 1 month to less than 18 years; Cohort 2:

age 1 month to less than 2 years at the time of informed consent/assent. Children age 1 month to less than 2 years will be enrolled only after approval is obtained for a Substantial Protocol Amendment outlining the dose schedule for this age range.

• Have a diagnosis of epilepsy with a pediatric epileptic syndrome (Cohort 1) or epilepsy with partial-onset seizures (POS) with or without secondary generalization (Cohort 2).

• Have had 4 or more seizures during the 4-week screening/baseline period.

• Have had brain imaging (example, magnetic resonance imaging [MRI] scan or computed tomography [CT] [or ultrasound for less than 1 year old]) before screening visit that ruled out a progressive cause of epilepsy.

• Currently maintained on stable doses of 1 to a maximum of 4 approved antiepileptic drugs (AEDs). A prescription medical marijuana (including products containing cannabidiol) is counted as 1 of the maximum of 4 allowed AEDs; however, it cannot be the only concomitant AED if this product is not an approved AED in the country where the study site is located. Doses must be stable for at least 4 weeks (at least 2 weeks for participant less than [<] 6 months old) before Visit 1; only 1 EIAED (defined as carbamazepine, phenytoin, oxcarbazepine, or eslicarbazepine) out of the maximum of 4 AEDs is allowed.

Exclusion Criteria:

• Current or history of pseudo-seizures (psychogenic nonepileptic seizures) within approximately 5 years before screening visit.

• Have a history of status epilepticus that required hospitalization within 6 months before screening visit.

• Have an unstable psychiatric diagnosis that may confound participants' ability to participate in the study or that may prevent completion of the protocol specified tests (example, significant suicide risk, including suicidal behavior and ideation within 6 months before screening visit 1, current psychotic disorder, acute mania).

• Any suicidal ideation with intent with or without a plan within 6 months before randomization visit (answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the C-SSRS) in participants aged 6 and above or based on the opinion of the Investigator for participants less than 6 years.

• Are scheduled or confirmed or both to have epilepsy surgery within 6 months after screening visit ; however, those who have previously documented "failed" epilepsy surgery will be allowed.

• Have a progressive central nervous system (CNS) disease, including degenerative CNS diseases and progressive tumors.

• Benzodiazepines for any indications other than epilepsy (example, anxiety/sleep disorders) prohibited from 1 month before Visit 1 and during the study. Benzodiazepines for seizure control are allowed.

• A vagal nerve stimulator (VNS), responsive neurostimulator (RNS), or deep brain stimulator (DBS) implanted less than 5 months before screening visit or changes in parameter less than 4 weeks before screening visit (or thereafter during the study).

• Use of perampanel within 30 days before screening visit, or perampanel was discontinued due to adverse reactions (perampanel-related) or lack of efficacy in case of previous exposure.